Back

Egle Therapeutics reports selective Treg expansion for EGL-003, plans Q4 2026 dermatitis trial

Verifying
  • Egle Therapeutics reported positive Phase 1 results for the Treg-selective IL-2 agonist EGL-003.
  • EGL-003 produced approximately 8- to 21-fold expansion of activated Tregs across four dose levels.
  • Egle plans an atopic dermatitis proof-of-concept study beginning in Q4 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.